|Bid||40.41 x 1800|
|Ask||40.42 x 2900|
|Day's Range||40.13 - 40.50|
|52 Week Range||39.23 - 56.32|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||7.41|
|Earnings Date||May 02, 2023|
|Forward Dividend & Yield||1.64 (4.02%)|
|Ex-Dividend Date||Jan 26, 2023|
|1y Target Est||50.97|
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Moderna’s CEO on Wednesday defended a plan to more than quadruple the company’s COVID-19 vaccine price, but he also said the drugmaker will work to ensure patients continue paying nothing at drugstores or clinics. Stephane Bancel told the Senate Committee on Health, Education, Labor and Pensions that the drugmaker will charge a list price of around $130 per dose for the vaccine in the U.S. More than 270 million doses of Moderna’s original COVID-19 vaccine and booster shots have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention.
Is Pfizer stock a buy or a sell after the company announced its $43 billion plan to buy Seagen? Is PFE stock a buy or a sell?
The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, a federal agency said on Tuesday. The Union for Affordable Cancer Treatment, a patient group, had first filed a petition calling on the National Institutes of Health (NIH) to use its authority to lower the drug's price in March 2016. The NIH said in a letter made public on Tuesday that its analyses in response to the petition found that the prostate cancer treatment was widely available.